IsomAb: A Beacon of Hope for Diabetic Peripheral Arterial Disease
February 21, 2024, 10:00 am
IsomAb, a biopharmaceutical company based in Nottingham, UK, has secured a significant £7.5 million in funding to advance its groundbreaking treatment for diabetic peripheral arterial disease (PAD). Led by CEO Jackie Turnbull, IsomAb focuses on developing isoform specific antibodies to restore blood flow in patients with PAD, a condition where arteries in the legs and feet become blocked by fatty deposits, leading to a lack of blood flow.
Founded in 2022 as a spin-out from the University of Nottingham by Prof. David Bates and Prof. Steve Harper, IsomAb's innovative approach targets the protein VEGF-A165b, which inhibits the angiogenesis process in diabetics, preventing the formation of new blood vessels. By developing an antibody to counteract the effects of this protein, IsomAb aims to provide a life-changing treatment for patients at risk of amputation due to PAD.
The recent funding round, led by Broadview Ventures and supported by MEIF Proof of Concept & Early Stage Fund, Mercia Ventures, and existing investor SCVC, will enable IsomAb to conduct further studies in preparation for clinical trials. CEO Jackie Turnbull expressed excitement about the potential of their lead program, emphasizing the importance of addressing the unmet medical needs of patients with metabolic syndrome and Type II diabetes.
With a focus on improving human health in cardiovascular disease, Broadview Ventures sees IsomAb's approach as highly innovative and promising for millions of patients worldwide suffering from peripheral artery disease. The funding injection will propel IsomAb's mission to revolutionize the treatment landscape for diabetic PAD, offering hope and healing to those in need.
IsomAb's dedication to advancing novel therapies for peripheral arterial disease underscores their commitment to transforming the lives of patients facing the debilitating effects of this condition. Through their pioneering research and strategic partnerships, IsomAb stands as a beacon of hope in the fight against diabetic peripheral arterial disease, bringing new possibilities and renewed optimism to those in search of effective treatments.
Founded in 2022 as a spin-out from the University of Nottingham by Prof. David Bates and Prof. Steve Harper, IsomAb's innovative approach targets the protein VEGF-A165b, which inhibits the angiogenesis process in diabetics, preventing the formation of new blood vessels. By developing an antibody to counteract the effects of this protein, IsomAb aims to provide a life-changing treatment for patients at risk of amputation due to PAD.
The recent funding round, led by Broadview Ventures and supported by MEIF Proof of Concept & Early Stage Fund, Mercia Ventures, and existing investor SCVC, will enable IsomAb to conduct further studies in preparation for clinical trials. CEO Jackie Turnbull expressed excitement about the potential of their lead program, emphasizing the importance of addressing the unmet medical needs of patients with metabolic syndrome and Type II diabetes.
With a focus on improving human health in cardiovascular disease, Broadview Ventures sees IsomAb's approach as highly innovative and promising for millions of patients worldwide suffering from peripheral artery disease. The funding injection will propel IsomAb's mission to revolutionize the treatment landscape for diabetic PAD, offering hope and healing to those in need.
IsomAb's dedication to advancing novel therapies for peripheral arterial disease underscores their commitment to transforming the lives of patients facing the debilitating effects of this condition. Through their pioneering research and strategic partnerships, IsomAb stands as a beacon of hope in the fight against diabetic peripheral arterial disease, bringing new possibilities and renewed optimism to those in search of effective treatments.